



Blocking CLEC14A-MMRN2 binding inhibits
sprouting angiogenesis and tumour growth




Other (please specify with Rights Statement)
Document Version
Peer reviewed version
Citation for published version (Harvard):
Noy, PJ, Lodhia, P, Khan, K, Zhuang, X, Ward, DG, Verissimo, AR, Bacon, A & Bicknell, R 2015, 'Blocking
CLEC14A-MMRN2 binding inhibits sprouting angiogenesis and tumour growth', Oncogene.
https://doi.org/10.1038/onc.2015.34
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Final published version appears in Oncogene, available at: http://www.nature.com/onc/journal/vaop/ncurrent/full/onc201534a.html.
Checked July 2015
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Mar. 2020
 1 
Title: Blocking CLEC14A-MMRN2 binding inhibits sprouting 
angiogenesis and tumour growth. 
 
Authors: Noy PJ1, Lodhia P1, Khan K1, Zhuang X1, Ward DG2, 
Verissimo AR1, Bacon A3, Bicknell R1. 
 
Affiliations: 1-Angiogenesis Laboratory, Institute for Biomedical 
Research, Schools of Immunity and Infection and Cancer Sciences, 
College of Medical and Dental Sciences, University of Birmingham, UK 
2-Institute of Cancer Studies, School of Cancer Sciences, University 
of Birmingham, UK 
3-School of Immunity and Infection, Institute for Biomedical 
Research, The Medical School, University of Birmingham, UK 
 
Corresponding Author: Roy Bicknell, Angiogenesis Laboratory, 
Institute for Biomedical Research, The Medical School, University of 
Birmingham, Edgbaston, Birmingham B15 2TT, UK 
Telephone:  (44)-121-4144085 
Email:   r.bicknell@bham.ac.uk 
 
Running Title: CLEC14A-MMRN2 interaction in angiogenesis 
 
Funding: PN was funded by Cancer Research UK (CRUK, grant 
number C4719/A6766 to RB). AV was funded by the Portuguese 
Fundacao para a Ciencia and tecnologia. XZ was funded by a 
knowledge transfer partnership (KTP007696) from the Technology 
Strategy Board. PL is funded by MRC and the University of Birmingham 
and KK is funded by the University of Birmingham. The University of 
Birmingham Transgenic Mouse Facility is part of the MRC Centre for 
Immune Regulation. 
 





We previously identified CLEC14A as a tumour endothelial marker. 
Here we show CLEC14A is a regulator of sprouting angiogenesis in vitro 
and in vivo. Using a HUVEC spheroid sprouting assay we found CLEC14A 
to be a regulator of sprout initiation. Analysis of endothelial sprouting 
in aortic ring and in vivo subcutaneous sponge assays from clec14a+/+ 
and clec14a-/- mice revealed defects in sprouting angiogenesis in 
CLEC14A deficient animals. Tumour growth was retarded and 
vascularity reduced in clec14a-/- mice. Pulldown and co-
immunoprecipitation experiments confirmed MMRN2 binds to the 
extracellular region of CLEC14A. The CLEC14A-MMRN2 interaction was 
interrogated using mouse monoclonal antibodies. Monoclonal 
antibodies were screened for their ability to block this interaction. 
Clone C4 but not C2 blocked CLEC14A-MMRN2 binding. C4 antibody 
perturbed tube formation and endothelial sprouting in vitro and in 
vivo, with a similar phenotype to loss of CLEC14A. Significantly, 
tumour growth was impaired in C4 treated animals and vascular 
density was also reduced in the C4 treated group. We conclude that 
CLEC14A-MMRN2 binding has a role in inducing sprouting angiogenesis 
during tumour growth, that has the potential to be manipulated in 
future anti-angiogenic therapy design. 
 






It is well established that solid tumour growth relies on the 
recruitment of endothelial cells and ultimately blood vessels from the 
surrounding healthy tissue. These recruited blood vessels deliver 
oxygen and nutrients, through blood flow, to the tumour. A primary 
mechanism of this recruitment is through sprouting angiogenesis of 
vessels adjacent to the tumour arising from tumour-derived release of 
VEGF. Sprouting angiogenesis proceeds by initial formation of a tip cell 
from a resting endothelial cell. The tip cell then migrates away from 
the existing vessel leaving dividing stalk cells behind it and creating 
the new sprout. Sprouting angiogenesis is a tightly regulated process, 
where the main regulatory components are VEGFR2, Notch and 
Angpoietin/Tie2 signalling pathways with cross-talk been these systems 
essential for direction, growth and cell specification.1,2 However, 
recent studies have highlighted the role of multiple other pathways as 
regulators of this process, including factors involved in glycolysis,3 PKA 
signalling,4 as well as new regulators of extracellular matrix 
composition.5,6 Manipulation of these factors has also been shown to 
suppress angiogenic sprouting in vitro and in vivo. 
Targeting angiogenesis in cancer has many therapeutic advantages, 
including efficient delivery to target tissue type, stable genetic 
profile, and lower potential for side effects than conventional 
chemotherapy. Current anti-angiogenic therapies in the clinic primarily 
target the VEGF signalling pathway, but with limited success.7 More 
recent efforts to develop effective anti-angiogenic therapies have 
focussed on understanding and targeting the endothelial tip and stalk 
cells during sprouting angiogenesis.2 For this to be effective, greater 
knowledge is required to understand the pathways involved in tip cell 
formation and behaviour. 
CLEC14A is a single-pass transmembrane glycoprotein that belongs 
to the vascular expressed C-type lectin family 14, whose other 
members include CD248/TEM1/Endosialin, Thrombomodulin and CD93.8 
Although functionally CLEC14A is relatively unstudied, available data 
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suggests that manipulation of CLEC14A levels or function blocking 
antibodies will regulate endothelial migration possibly through an 
interaction with the extracellular matrix.9-12 CLEC14A was originally 
identified to be an endothelial specific gene that is highly upregulated 
on vessels associated with multiple solid tumours.9 More recent work 
has shown CLEC14A as part of a “common angiogenesis signature” in a 
meta-analysis of 121 head and neck squamous cell carcinomas, 959 
breast cancers and 170 clear cell renal cell carcinomas.13 MMRN2, an 
endothelial specific member of the emilin family and component of 
the extracellular matrix,14,15 was recently found as an extracellular 
interacting protein for CLEC14A and MMRN2 and CLEC14A were both 
upregulated in tumour vasculature during tumour progression .11 Thus, 
although it is becoming apparent that CLEC14A has a likely function in 
the tumour vasculature our knowledge is restricted. In this study we 
have investigated CLEC14A in sprouting angiogenesis and for the first 




CLEC14A regulates sprouting angiogenesis in vitro. 
 
We previously described a role for CLEC14A in endothelial migration 
and tube formation in vitro.9 To investigate the role of CLEC14A in 
sprouting angiogenesis in vitro, HUVEC spheroids were generated from 
HUVECs treated with siRNAs targeting clec14a or a non-complementary 
siRNA duplex. Knockdown of clec14a expression was confirmed at the 
mRNA level by qPCR for both clec14a targeted siRNAs with an average 
reduction of 84% and 83% across three experiments (Figure 1A) and at 
the protein level by Western blot analysis of protein extracts probed 
with an anti-CLEC14A polyclonal antisera (Figure 1B). VEGF induced 
sprouting from CLEC14A knockdown spheroids was impaired, 
knockdown spheroids produced on average 6.9 or 6.4 sprouts per 
spheroid for duplex 1 or 2 respectively, compared to 13.2 for control 
cells (Figures 1C and 1D). To determine the role of CLEC14A in 
tip/stalk cell formation, control HUVECs and knockdown HUVECs were 
stained either red or green and mixed, prior to spheroid formation and 
induced sprouting (Figure 1E). Knockdown of CLEC14A reduced the 
percentage of cells at the tip position (33%) compared to control cells 
(67%), however, there was no effect on the percentage of stalk cells 
that were derived from CLEC14A knockdown HUVECs (Figure 1F). These 
data suggest CLEC14A has a role in sprout initiation and migration. 
 
CLEC14A regulates sprouting angiogenesis in vivo. 
 
Previously published data for CLEC14A has demonstrated its role in 
endothelial biology in vitro, however its in vivo role has not been 
reported. To investigate the role of CLEC14A in vivo and ex vivo, mice 
were generated to replace the clec14a coding sequence with a lacZ 
reporter (Figure 2A). Breeding was normal (Supplemental Table 1). 
Aortas were isolated from clec14a+/+ and clec14a-/- mice. Extracted 
cDNA was analysed by qPCR and confirmed loss of the clec14a coding 
region but expression of the 5’ and 3’ untranslated regions were 
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retained (Figure 2B) and expression of mmrn2 was unaltered 
(Supplemental Figure 1). Loss of CLEC14A at the protein level was also 
confirmed by Western blot analysis of lung tissue lysates (Figure 2C). 
To confirm the role of CLEC14A in sprouting angiogenesis in a 
multicellular three dimensional co-culture, aortas were isolated, cut 
into rings and embedded in collagen. Cellular outgrowth was 
stimulated by VEGF and monitored over 7 days before end-point 
quantitation of endothelial sprouting. Again, loss of CLEC14A impaired 
endothelial sprout outgrowth and migration (Figure 2D). Aortic rings 
from wildtype mice produced over double the number of tubes 
compared to that observed for CLEC14A knockout mice (30.6 tubes 
compared to 13.4 tubes respectively) (Figure 2E). In addition, the 
maximum migration, which is defined by the furthest distance 
migrated away from each aortic ring, was also reduced in knockout 
cultures (Figure 2F). To assess whether CLEC14A has a similar function 
in vivo, sponge barrels were implanted subcutaneously into CLEC14A 
knockout mice. Cellular infiltration and neo-angiogenesis were 
stimulated using bFGF injections into the sponge every two days for 
two weeks. Macroscopic analysis of sponge sections stained with 
haematoxylin and eosin revealed impaired infiltration of cells into the 
sponge in clec14a-/- animals (Figures 2G and 2H). In addition, 
vascularity was significantly reduced (p<0.01) for  clec14a-/- animals 
(Figure 2I). To confirm the endothelial cells lining the neoangiogenic 
vessels express clec14a in this model, sponges and livers from CLEC14A 
KO mice were stained with x-gal. Strong x-gal staining was observed on 
blood vessels within the sponge compared to matched liver sections 
(Figure 2J). From these data we can conclude that mouse CLEC14A 
expression regulates endothelial migration and angiogenic sprouting in 
vivo, as well as in vitro, and CLEC14A is upregulated on sprouting 
endothelium. 
 
CLEC14A promotes tumour growth. 
 
CLEC14A expression is found highly up-regulated on human tumour 
vessels compared to vessels from healthy tissue, suggesting that cancer 
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therapies could be targeted against CLEC14A.9 Therefore, to 
investigate whether loss of CLEC14A effects tumour growth, we used 
the syngeneic Lewis lung carcinoma (LLC) model. For this 1x106 LLC 
cells were injected subcutaneously into the right flank of either 
clec14a+/+ or clec14a-/- mice. Tumour growth was impaired in the 
clec14a-/- mice compared to clec14a+/+ littermates (Figure 3A). This 
was confirmed by three independent experiments. Excised tumours 
taken from clec14a-/- mice were smaller in size (Figure 3B) and smaller 
in weight (Figure 3C) than clec14a+/+ littermates.  To determine 
whether the vascular density within these tumours was also effected, 
tissue sections were stained with an anti-CD31 antibody. Analysis 
shows a reduced density of discrete vessels (Figures 3D and 3E) and 
reduced percentage endothelial coverage (Figure 3F). In healthy 
tissues, highest expression of x-gal in sections from clec14a-/- mice was 
seen in the liver vessels (black arrow) but was vastly less than that 
seen on both mature vessels, with erythrocyte filled lumens (Figure 
3G, black arrows), and immature microvessels within the tumour 




Identification and confirmation of CLEC14A-MMRN2 interaction. 
 
To identify potential binding partners for the extracellular domain 
for CLEC14A, we first purified CLEC14A extracellular domain protein 
tagged with human Fc. This protein or Fc alone was incubated with 
HUVEC whole cell lysates and precipitated using protein A agarose 
beads. The precipitated proteins were then washed and separated on a 
SDS-PAG. Seven gel regions were excised, digested and analysed by 
mass spectrometry. The most abundant protein identified was MMRN2 
with 12 peptides (11 unique), and no peptides in the corresponding 
control pulldown fraction. Western blot analysis of the precipitates 
confirmed the presence of MMRN2 in the CLEC14A-ECD-Fc pull-down 
and was not detected in the Fc alone pull-down (Figure 4A). To further 
confirm this interaction, endogenous CLEC14A was immunoprecipitated 
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from HUVEC whole cell lysates. Western blot analysis confirmed 
MMRN2 co-precipitation in the CLEC14A precipitate but was not 
detected in the IgG control (Figure 4B). 
 
Development and validation of CLEC14A monoclonal antibodies. 
 
To further our understanding of CLEC14A, we next produced cross-
species reactive antibodies. To enable this, murine CLEC14A protein 
with a human Fc tag was expressed in HEK293T cells and purified on a 
protein A column. Mice were then immunised with 50 µg mCLEC14A 
with complete Freund’s adjuvant to break tolerance. Clones were 
screened for activity against human CLEC14A or human Fc. To confirm 
the clones could recognise cell bound CLEC14A, HEK293T cells 
overexpressing HA-CLEC14A were stained with clone C2 or C4 or a 
monoclonal HA tag antibody. FACs analysis shows increased 
fluorescence for each of the antibodies in the HA-CLEC14A 
overexpressing cells compared to control transfected cells (Figure 5A). 
To confirm that antibodies recognise the endogenous form of CLEC14A, 
these clones were used to stain HUVEC treated with control or clec14a 
targeted siRNAs. Control HUVEC were stained strongly by clone C2 and 
C4 and this staining was reduced to isotype control levels by 
knockdown of CLEC14A (Figure 5B). These results confirmed the 
specificity of the CLEC14A monoclonal antibodies. 
To determine whether the C2 and C4 clones bind to the same region 
of CLEC14A, HUVECs were pre-treated with BSA, C2 or C4 antibody 
prior to C2-FITC staining. C2 incubation blocked C2-FITC staining 
effectively, but C4 had little effect (Figure 5C). The same pre-
treatment was repeated prior to C4-FITC staining. C2 antibody did not 
effect C4-FITC staining however, HUVECs pre-treated with C4 showed 
reduced binding of C4-FITC (Figure 5D). From these results we can 
conclude that C2 and C4 bind to discrete regions of CLEC14A. 
 
 
A CLEC14A monoclonal antibody blocks CLEC14A-MMRN2 binding. 
 
 9 
To determine whether either of these CLEC14A monoclonal 
antibodies could inhibit the binding of MMRN2 to CLEC14A, CLEC14A-
ECD-Fc was pre-incubated with increasing concentrations of mIgG1, or 
C2, or C4, prior to incubation with lysates from HEK293T cells 
overexpressing MMRN2. Precipitates were then separated and probed 
for MMRN2 or CLEC14A-ECD-Fc. MMRN2 binding was observed for 
CLEC14A-ECD-Fc precipitates blocked with mIgG1 or C2 (Figure 5E) but 
no MMRN2 binding was observed in the C4 blocked precipitates (Figure 
5F). This confirms that the C4 but not the C2 monoclonal antibody 
blocks MMRN2 binding to CLEC14A. 
 
CLEC14A-MMRN2 blocking antibody inhibits tube formation and 
sprouting angiogenesis in vitro and in vivo. 
 
We previously showed that CLEC14A expression regulates 
endothelial cell migration and tube formation.9 To assess whether C2 
or C4 have a role in modulating endothelial cell migration, wounds 
were scratched into HUVEC monolayers and treated with 20 µg/ml 
mIgG1, C2 or C4. Wound closure was assessed at 16-24 hours. However, 
no difference was observed between any of the treatments (data not 
shown). Antibody treatment also had no effect on CLEC14A expression 
(Supplemental Figure 2). To determine whether the CLEC14A 
monoclonal antibodies have regulatory properties in in vitro tube 
formation, HUVECs were plated onto Matrigel and treated with either 
mIgG1, C2 or C4 for 16hrs. The C2 treatment had no effect on tube 
formation compared to the mIgG1 control; however, C4 treatment 
effected branching and meshes (Figure 6A). The number of meshes 
(Figure 6B) was decreased in the C4 treatment group, with a 
corresponding increase in the number of branches (Figure 6C) for this 
treatment group compared to the control and C2 groups. Furthermore, 
C4 treated HUVECs have decreased branch length (Figure 6D). These 
data suggest that C4 inhibits the sprouting or sensing and delays 
interconnectivity of the tubes, but the second CLEC14A targeted 
antibody (C2) was without activity on tube formation. 
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To investigate how disruption of the MMRN2-CLEC14A interaction 
effects sprouting in vitro, we treated HUVEC spheroids with 20 µg/ml 
C4 or C2 or mIgG1 control antibodies. Control, mIgG1 treated, 
spheroids formed sprouts after 16 hours as expected (Figure 6E). C2 
treatment had no effect on sprouting, but C4 treatment inhibited 
sprout formation by 50 % (Figures 6E and 6F). To further investigate, 
aortic ring cultures were also supplemented with 20 µg/ml C4 or C2 or 
mIgG1 antibodies. Endothelial outgrowth and tube formation was well 
established after 7 days culture in the presence of mIgG1 (Figure 6G). 
C4 antibody effectively inhibited tube outgrowth, however C2 antibody 
was inactive in regulating tube/sprout formation from aortic rings 
(Figures 6G and 6H). 
To confirm the importance of MMRN2, HUVECs were treated with 
mmrn2 targeted siRNA or a control siRNA duplex. Knockdown of mmrn2 
expression was confirmed by qPCR (Figure 6I). Endothelial sprouting 
from MMRN2 knockdown HUVEC spheroids formed 8.9 (duplex 1) or 8.6 
(duplex 2) sprouts per spheroid, compared to 15.7 for control spheroids 
(Figure 6J). 
To evaluate the role of the MMRN2-CLEC14A interaction in vivo, 
subcutaneous sponge implants were used. Sponge infiltration was 
stimulated as previously described with the addition of either 10 µg 
mIgG1 or C4 antibody. Total cellular sponge infiltration was 
significantly reduced (p<0.01) in the C4 treatment group compared to 
the mIgG1 controls (Figures 6K and 6L). Vascular density of the invaded 
sponge was also reduced for the C4 antibody group (Figure 6M). These 
data demonstrate that the MMRN2-CLEC14A interaction promotes in 
vivo angiogenesis. 
 
CLEC14A-MMRN2 blocking antibody inhibits tumour growth. 
 
As CLEC14A expression is most abundant on tumour endothelial cells 
and CLEC14A expression is associated with MMRN2 in tumours,11 we 
hypothesised that disruption of this interaction would perturb tumour 
growth. Therefore, mice with LLC tumours were injected 
intraperitoneally twice per week with 10 µg C4 or mIgG1 (control) for 
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the duration of the experiment. Tumour growth was slowed for mice 
treated with C4 antibody compared to the control, mIgG1, treatment 
group (Figure 7A). Tumours from the C4 treated mice were smaller in 
size (Figure 7B) and weight (Figure 7C) than control animals. Again we 
examined the vascular density within these tumours. Tissue sections 
were stained with an anti-CD31 antibody and fluorescent analysis 
revealed a reduced density of discrete vessels (Figures 7D and 7E) and 
the percentage endothelial coverage (Figure 7F). Suggesting that 
CLEC14A binding to MMRN2 is an important functional component of 




CLEC14A is one of a small group of endothelial genes that contribute 
to tumour angiogenesis in multiple tumour types.9,13 Here we 
demonstrate that through loss of CLEC14A, tumour growth is inhibited 
in vivo (Figure 3). A similar phenotype has also been observed for other 
tumour endothelial markers, such as TEM8,16 Endoglin,17 Galectin,18 
ELTD1,13 and Endosialin,19 this demonstrates the importance of these 
tumour endothelial expressed genes in vascularisation and tumour 
growth. Although many groups have focused on factors involved in 
physiological sprouting angiogenesis, these tumour endothelial 
expressed genes could deliver tumour anti-angiogenic therapeutic 
potential.20 
Upregulation of CLEC14A has been observed in human tumours9,13,21 
and murine models of pancreatic and cervical cancer11 which supports 
our findings that clec14a expression is upregulated on tumour vessels 
in the LLC model (Figure 3). CLEC14A has been shown to regulate 
multiple aspects of endothelial biology including adhesion,10,12 
migration,9,10,12 tube formation,9-11 and we now demonstrate, as we 
first predicted,22 it is also important for sprouting angiogenesis in vitro 
and in vivo (Figures 1 and 2). We can infer that this role of CLEC14A is 
through endothelial-endothelial interactions or endothelial-
extracellular matrix interactions, because in vitro HUVEC sprouting is 
perturbed by CLEC14A knockdown, suggesting the presence of other 
cell types is dispensable. We also observed for the first time 
upregulation of clec14a expression on neoangiogenic vessels in the 
subcutaneous sponge assay (Figure 2). This is expected as newly 
formed endothelial sprouts have been modelled to experience 
extremely low shear stress (0.2 Pa) from the 4.2 µm of the bifurcation 
point to the tip of the sprout,23 and clec14a expression is known to be 
upregulated by low shear stress.9 Therefore, it is possible that 
CLEC14A has a role in regulating physiological sprouting angiogenesis 
also, however, its role will likely be limited by the co-expression of 
MMRN2. 
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Zanivan et al. identified MMRN2 as a component of the extracellular 
matrix that interacts with CLEC14A.11 We independently verified this 
interaction through pulldown of proteins from HUVEC lysates using the 
extracellular domain of CLEC14A, as well as co-immunoprecipitation of 
the endogenous proteins (Figure 4). Through the generation and 
validation of CLEC14A monoclonal antibodies, we identified two 
antibodies that bind to discrete regions of CLEC14A (Figure 5C and 5D) 
and have shown that the C4 but not the C2 clone blocks the interaction 
of CLEC14A with MMRN2 (Figure 5E and 5F). To probe the function of 
the CLEC14A-MMRN2 interaction, we used the C4 antibody in Matrigel 
tube forming assays and found an increase in branching and decrease 
in evolved meshes (Figure 6). Knockdown by siRNA or targeting with 
polyclonal CLEC14A antisera has a similar effect on branching in this in 
vitro Matrigel assay.9 However, another monoclonal antibody that 
binds CLEC14A but does not block MMRN2 binding had no effect (Figure 
6). In a study using phage display to develop IgGs targeting the c-type 
lectin domain (CTLD) of CLEC14A, some of the generated IgGs reduced 
HUVEC cell migration and tube formation, although not all of the 
clones tested.12 As our monoclonal antibody has a similar function it is 
possible that the MMRN2 binding site is within the CTLD region of 
CLEC14A, although further work is required to confirm this. In vitro 
and in vivo sprouting assays treated with C4 antibodies also 
demonstrated the role of the CLEC14A-MMRN2 interaction for 
endothelial sprouting (Figure 6). Lorenzon et al previously observed 
anti-angiogenic activity with soluble MMRN2 protein.33 This data 
supports our model, as soluble MMRN2 protein could be binding to 
CLEC14A and disrupting the interaction of CLEC14A with MMRN2 in the 
extracellular matrix (Figure 8). Finally, we found that the CLEC14A-
MMRN2 interaction is important for tumour growth (Figure 7), C4 
treatment recapitulated tumour growth and reduced tumour 
vascularity as seen in clec14a-/- mice (Figure 3). Antibody inhibition of 
tumour endothelial marker function has been suggested as a mode of 
anti-angiogenic therapy for TEM824 and our studies corroborate this 
approach. Although in this example no ligand or mode of activity was 
identified. This is the first time that CLEC14A and a specific 
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extracellular interaction has been shown to be important for tumour 
growth, and suggests a hitherto unknown avenue into new anti-
angiogenic therapies. 
 15 




For Western blotting and immunoprecipitation; primary antibodies: 
sheep polyclonal anti-human CLEC14A (R&D systems), mouse 
monoclonal anti-human Tubulin (Sigma), mouse polyclonal anti-human 
MMRN2 (Abnova); secondary antibodies: goat polyclonal anti-mouse IgG 
conjugated to horseradish peroxidase (HRP) (Dako), donkey polyclonal 
anti-sheep IgG conjugated to HRP (R&D systems). For 
immunofluorescence; primary antibodies: rabbit polyclonal anti-murine 
PECAM (Santa Cruz); secondary antibodies: donkey polyclonal anti-
rabbit conjugated to Alexa Fluor488 (Invitrogen). For flow cytometry; 
primary antibodies: mouse monoclonal anti-HA tag (CRUK), mouse 
monoclonal anti-CLEC14A (C2, C4 described below); secondary 






For protein production; lentiviral plasmids psPAX2 (lentiviral 
packaging; Addgene), pMD2G (Envelope plasmid; Addgene) and pWPI 
hCLEC14A-ECD-Fc (lentiviral mammalian expression plasmid containing 
IRES-EGFP; Addgene) were used. pWPI hCLEC14A-Fc and mCLEC14A-Fc 
was generated by initial PCR subcloning from clec14a IMAGE clone 
(Origene) into pcDNA3-Fc plasmid. The primers used were as follows: 
human CLEC14A fwd - 
5’TAGTAGGAATTCGAGAGAATGAGGCCGGCGTTCGCCCTG3’; human 
CLEC14A rev - 
5’AGAACCGCGGCCGCTGGAGGAGTCGAAAGCCTGAGGAGT3’; murine 
CLEC14A fwd - 
5’TAGTAGGAATTCGAGAGAATGAGGCCAGCGCTTGCCCTG3’; murine 
CLEC14A rev - 5’CTACTAGCGGCCGCTCGTGGAAGAGGTGTCGAAAGT3’. 
EcoR1 and Not1 restriction sites were used to insert CLEC14A. A further 
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round of PCR subcloning was performed to transfer the CLEC14A-Fc 
fusion into pWPI. The primers used were as follows: human CLEC14A 
fwd - 5’TAGTAGTTAATTAAGAGAGAATGAGGCCGGCGTTC3’; murine 
CLEC14A fwd - 5’TAGTAGTTAATTAAGAGAGAATGAGGCCAGCGCTT3’; 
human Fc rev - 5’CTACTAGTTTAAACTCATTTACCCGGAGACAGGGA3’. For 
this step, Pac1 and Pme1 restriction sites were used. 
MMRN2 mammalian expression plasmid was constructed by PCR 
cloning from mmrn2 IMAGE clone (Thermo) into pHL-Avitag3,25 using 
the following primers: fwd - CCGGACCGGTCAGGCTTCCAGTACTAGCC; 
rev - CGGGGTACCGGTCTTAAACATCAGGAAGC. Age1 and Kpn1 




Human Umbilical Vein Endothelial Cells were isolated as described 
previously.9 Umbilical cords were obtained from Birmingham Women's 
Health Care NHS Trust with informed consent. HUVECs and HEK293T 
cells were cultured as previously described.34  
SiRNA transfections in HUVEC were performed as previously 
described for clec14a.9 For mmrn2 pre-designed siRNA duplexes were 
used (Ambion silencer select - ID S36387 and S36388). Lentivirus was 
produced in HEK293T cells by transient transfection with the lentiviral 
packaging, envelope and expression plasmids above.  Plasmids were 
incubated in OptiMEM (Invitrogen) with polyethylenimine (36 µg/ml) at 
a 1:4 ratio for 10 minutes at room temperature prior to adding to 
HEK293T cells in cDMEM. Media supernatant was used to transduce 
fresh HEK293T cells. GFP positive HEK293T cells were sorted and used 
for protein production. Expression of MMRN2 in HEK293T cells was 





cDNA was prepared using the High-Capacity cDNA Archive kit 
(Applied Biosystems), from 1 µg of extracted total RNA. qPCR reactions 
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were performed with Express qPCR supermix (Invitrogen) on a RG-3000 
(Corbett, Manchester, UK) thermocycler. Primers for human clec14a 
and flotillin-2 were as previously described.9 Primers for murine 
clec14a 5’ UTR, CDS and 3’ UTR and murine beta-actin, are as follows: 
5’UTR fwd – TTCCTTTTCCAGGGTTTGTG; 5’ UTR rev – 
GCCTACAAGGTGGCTTGAAT; CDS fwd – AAGCTGTGCTCCTGCTCTTG; CDS 
rev – TCCTGAGTGCACTGTGAGATG; 3’ UTR fwd – 
CTGTAGAGGGCGGTGACTTT; 3’ UTR rev – AGCTGCTCCCAAGTCCTCT; 
mACTB fwd – CTAAGGCCAACCGTGAAAAG; mACTB rev - 
ACCAGAGGCATACAGGGACA. Relative expression ratios were calculated 
according to the efficiency adjusted mathematical model.27 
 
Western blotting and immunoprecipitation. 
 
Whole cell protein lysates were made and co-immunoprecipitation 
experiments were performed as previously described,28 except protein 
was extracted from 2x107 HUVECs. For initial isolation of CLEC14A 
interacting proteins 5 µg CLEC14A-Fc or an equimolar amount of hFc 
was used. For endogenous immunoprecipitation experiments 0.4 µg 
anti-CLEC14A antibody or sheep IgG was used. For blocking 
experiments 5 µg CLEC14A-Fc or hFc were bound to protein G beads 
overnight in PBS. Beads were blocked for 5-6 hours in PBS containing 
20 % FCS (PAA). Bound CLEC14A-Fc or hFc protein was blocked with 
increasing concentrations of mIgG, C2 or C4 in binding buffer 
overnight. Lysates from MMRN2 transfected HEK293T cells were then 
incubated overnight with the bead complexes before washing and 
analysing by Western blot. Standard protocols were used for Western 




Cells were detached with cell dissociation buffer (Invitrogen), rinsed 
in PBS before incubation in blocking buffer (PBS, 3 % BSA, 1 % NaN3) for 
15 minutes. Subsequent staining using 10 µg/ml anti-HA tag (CRUK), 10 
µg/ml anti-CLEC14A (C2, C4 described below), as primary antibodies, 
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in blocking buffer for 30 minutes. Cells were rinsed in PBS and stained 
with goat polyclonal anti-mouse IgG conjugated to Alexa Fluor488 
(Invitrogen) in blocking buffer. Data (15,000 events/sample) were 
collected using a FACSCalibur apparatus (Becton Dickinson, Oxford, 
UK), and results were analysed with Becton Dickinson Cell Quest 
software. 
 
HUVEC spheroid sprouting assay and in vitro Matrigel tube forming 
assay. 
 
Generation of HUVEC spheroids and induction of endothelial 
sprouting in a collagen gel was performed as previously described,29 
using 1000 HUVECs per spheroid. Quantification was performed 16 
hours after embedding. To quantify sprout growth the number of 
sprouts were counted, the cumulative sprout length and the maximal 
sprout length was assessed. For two colour sprouting experiments, 
HUVECs were pre-labelled with orange and green CellTracker dyes 
(Invitrogen). After 24 hours spheroids were fixed in 4% formaldehyde 
and mounted with Vectorshield (Vector labs). Slides were imaged with 
an Axioskop2 microscope and AxioVision SE64 Rel4.8 software (Zeiss, 
Cambridge, UK). 
For the Matrigel tube forming assays 1.4 x105 HUVECs were seeded 
onto 70 µl basement membrane extract (Matrigel, BD Bioscience) in a 
12 well plate. After 16 hours, images were taken of 5 fields of view per 
well using a Leica DM IL microscope (Leica, Milton Keynes, UK) with a 
USB 2.0 2M Xli digital camera (XL Imaging LLC, Carrollton, TX, USA) at 
10x magnification. Images were analysed with the Angiogenesis 
analyser plugin for Image J (Carpentier G. et al., Angiogenesis Analyzer 
for ImageJ. 4th ImageJ User and Developer Conference proceedings) 







Culture media (CM) from CLEC14A-Fc expressing HEK293T cells was 
collected. CM was flowed over a HiTrap protein A HP column (GE 
healthcare, Amersham, UK) and protein eluted using a 0-100 % gradient 
of 100 mM sodium citrate (pH 3) before neutralising with 1 M Tris base. 
Fractions were run on a SDS-PAG and assessed for protein purity and 
specificity by Coomassie staining and Western blotting. Fractions 
containing similar concentrations of protein were combined and 
dialysed in PBS prior to functional assays. 
 
Monoclonal antibody generation. 
 
Mouse monoclonal antibodies were commercially prepared by 
Serotec Ltd (Oxford, UK) using the following protocol to break 
tolerance supplied by us. Purified mouse CLEC14A-Fc fusion protein 
was given at 50 µg in Freunds complete adjuvant subcutaneously. Two 
weeks later mice were given another 50 µg subcutaneously but this 
time in Freunds adjuvant. Mice were culled and spleens harvested for 
fusion two weeks later. 
 
Generation of clec14a-/- mice. 
 
Mice were housed at the Birmingham Biomedical Services Unit 
(Birmingham, UK). C57BL/6N VGB6 feeder-dependent embryonic stem 
cells containing the CLEC14A deletion cassette 
(Clec14atm1(KOMP)Vlcg; project ID VG10554) were procured from the 
Knockout Mouse Project (University of California, Davis, USA). The 
Transgenic Mouse Facility at the University of Birmingham generated 
chimeric mice by injection of embryonic stem cells into albino C57BL/6 
mice and were bred to C57BL/6 females to generate mice 
heterozygous for the cassette. Animal maintenance had appropriate 
Home Office approval and licensing. 
 
Aortic ring and murine subcutaneous sponge angiogenesis assay. 
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Aortas were isolated and processed for aortic ring assays in collagen 
as previously described.30 Tube/sprout outgrowth, maximal endothelial 
migration and total endothelial outgrowth was quantitated. The 
murine subcutaneous sponge angiogenesis assay was performed as 
previously described,31 with slight modification. Male C57 black mice 
were implanted with a subcutaneous sterile polyether sponge disc 
(10×5×5 mm) under the dorsal skin of each flank at day 0. 100 µl bFGF 
(40 ng/ml; R&D systems) was injected through the skin directly into 
the sponges every other day for 14 days. Sponges were excised on day 
14, fixed in 10 % formalin, and paraffin embedded. Sections were 
stained with haematoxylin and eosin, sponge cross-sections were taken 
using a Leica MZ 16 microscope (Leica, Milton Keynes, UK) with a USB 
2.0 2M Xli digital camera at ×1 magnification for cellular invasion 
analysis. Images captured by Leica DM E microscope (Leica, Milton 
Keynes, UK) at 40x magnification were analysed for vessel density. 
Vessel counts were assessed in five fields per section per sponge. All 
animal experimentation was carried out in accordance with Home 
Office License number PPL 40/3339 held by RB. 
 
Tumour implantation assays. 
 
106 Lewis lung carcinoma cells were injected subcutaneously into 
the flank of male mice at 8-10 weeks of age. Tumour growth was 
monitored by daily calliper measurements and after two-four weeks 
growth, tumour mass was determined by weight, fixed in 4 % PFA, 
paraffin embedded and serial sections cut at 6 µm.  
 
Immunofluorescence and X-gal staining. 
 
Immunofluorescence staining was performed as previously 
described.9  




Figure 1 - SiRNA knockdown of CLEC14A reveals a role for CLEC14A 
in endothelial sprouting. [A] SiRNA duplexes targeting CLEC14A can 
efficiently knockdown CLEC14A mRNA expression in HUVEC, as 
determined by qPCR. Relative expression was determined by 
normalising expression to flotillin2. [B] Knockdown of CLEC14A at the 
protein level was determined for both siRNAs by Western blot analysis. 
Tubulin was used as a loading control. [C] Representative images of 
sprout outgrowth after 16 hours for control or clec14a targeted siRNA 
treated HUVEC. Scale bars are equal to 100 µm. [D] Quantitation of 
sprouts for 27 spheroids (9 spheroids from 3 cords) for control and 
CLEC14A knockdown HUVEC; Kruskal-Wallis statistical test p<0.001. [E] 
Representative images of sprout outgrowth after 24 hours for mixed 
control (green) and clec14a targeted siRNA treated HUVEC (red). Scale 
bars are equal to 100 µm. [F] Quantitation of the percentage of tip and 
stalk cells derived from control (CON) and CLEC14A knockdown (KD) 
HUVEC; two-way ANOVA statistical test with Bonferroni post-tests *** = 
p<0.001, ns = not significant. 
 
Figure 2 - Loss of CLEC14A inhibits sprouting in vitro and in vivo. [A] 
Schematic diagram of clec14a gene in C57BL/6 (clec14a+/+) or 
C57BL/6(Clec14atm1(KOMP)Vlcg) (clec14a-/-) mice. [B] Quantitative PCR 
analysis of cDNA generated from three clec14a+/+ mice (white bars) and 
three clec14a-/- mice (black bars) for the 5’ untranslated region (UTR), 
coding sequence (CDS) and 3’ UTR of clec14a. Relative expression was 
determined by normalising expression to flotillin2. [C] Western blot 
analysis of CLEC14A protein expression in lung lysates from clec14a+/+ 
and clec14a-/- mice using polyclonal antisera against murine CLEC14A. 
Tubulin was used as a loading control. [D] Representative images of 
the aortic ring sprouting assay from clec14a+/+ and clec14a-/- mice. 
Scale bars are equal to 200 µm. Quantitation of tubes formed per ring 
[E], and quantitation of the longest distance migrated away from the 
aortic ring by an endothelial tube per aortic ring  [F], data from 48 
rings per genotype, 6 mice for each genotype; Mann-Whitney statistical 
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test p<0.001. [G] Representative images of haematoxylin and eosin 
stained sections of sponge implant from clec14a+/+ and clec14a-/- mice, 
sections at the centre of the sponge were analysed. Black and white 
images represent the masks generated during the threshold analysis for 
quantitation. [H] Quantitation of cellular invasion, by threshold 
analysis of haematoxylin and eosin stained cellular material within the 
sponge implants shown in G; Mann-Whitney statistical test p<0.05. [I] 
Quantitation of vessel density; Mann-Whitney statistical test p<0.001. 
[J] Sections of liver and sponge tissue stained with x-gal from clec14a-/- 
mice, counterstained with haematoxylin and eosin. Arrows indicate 
vessels stained with x-gal and the increased intensity in the sponge 
tissue compared to the liver. Scale bars are equal to 100 µm. 
 
Figure 3 - Loss of CLEC14A inhibits tumour growth. [A] Lewis lung 
carcinoma (LLC) tumour growth in clec14a+/+ (black line with dots) and 
clec14a-/- (black line with squares) mice; two-way ANOVA statistical 
analysis, * = p<0.05, ** = p<0.01, *** = p<0.001. [B] Representative 
images of LLC tumours. [C] Endpoint tumour weight for 7 clec14a+/+ 
(dots) and 7 clec14a-/- (squares) mice; Mann-Whitney statistical test 
p<0.001. [D] Representative images of immunofluorescent staining of 
LLC tumour sections stained for murine CD31. Scale bars are equal to 
100 µm. Quantitation of vessel density [E] and percentage endothelial 
coverage [F] from clec14a+/+ and clec14a-/- mice; Mann-Whitney 
statistical test p<0.0001. [G] Sections of liver and LLC tumour tissue 
from clec14a-/- mice stained with x-gal, counterstained with 
haematoxylin and eosin. Scale bars are equal to 100 µm. 
 
Figure 4 - MMRN2 binds to CLEC14A. [A] 20 µg CLEC14A-ECD-Fc or Fc 
was used to precipitate interacting partners. Precipitates and HUVEC 
lysates were separated on an SDS-PAG and blotted for MMRN2 (top 
panel) or CLEC14A-ECD-Fc (bottom panel). [B] CLEC14A was 
immunoprecipitated from HUVEC lysates using polyclonal antisera 
against CLEC14A. Immunoprecipitates were analysed by Western blot 
for MMRN2 (top panel) and CLEC14A (bottom panel). 
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Figure 5 - CLEC14A monoclonal antibodies block MMRN2-CLEC14A 
interaction. [A] HEK293T cells expressing HA-CLEC14A or an empty 
vector (CON) were stained with an HA tag antibody (column 1), or 
monoclonal antibodies against CLEC14A C2 (column 2) or C4 (column 
3). Cells were analysed by flow cytometry and displayed as histograms 
of increasing fluorescence (x-axis) versus counts (y-axis). [B] HUVECs 
transfected with negative control siRNA duplexes or siRNA duplexes 
targeting CLEC14A were probed with C2 or C4 antibodies and analysed 
as in A. [C] HUVECs were pre-treated with blocking buffer (-), 100 µg 
C2 antibody or 100 µg C4 antibody, prior to C2-FITC staining. Cells 
were analysed by flow cytometry. Geometric means were normalised 
to staining for the cells pre-treated with blocking buffer. [D] as for C, 
except stained with C4-FITC. [E] CLEC14A-Fc (5 µg) protein G agarose 
bead complexes were blocked with 7.5, 15, 30, µg mIgG or C2, prior to 
MMRN2 pulldown from HEK293T lysates. Precipitates were separated 
by SDS-PAGE and blotted for MMRN2 (upper panel) and CLEC14A-Fc 
(lower panel). [F] as in E, except C4 was used to block instead of C2. 
 
Figure 6 - MMRN2-CLEC14A interaction blocking antibody inhibits 
endothelial tube formation and sprouting in vitro and in vivo. HUVECs 
were plated onto Matrigel and grown in the presence of 20 µg/ml 
mIgG1 (CON), C2, or C4 antibodies for 16 hours. [A] Representative 
images. Scale bars are equal to 100 µm. Tube formation was analysed 
for number of meshes [B], number of branches [C] and the branch 
length [D]. Representative data from 1 of 3 independent experiments; 
Kruskal-Wallis statistical test, * = p<0.05, ** = p<0.01, ns = not 
significant. HUVEC spheroids embedded in a collagen gel were 
stimulated to sprout with VEGF supplemented with 20 µg/ml mIgG1 
(CON), C2 or C4. [E] Representative images. Scale bars are equal to 
100 µm. [F] Quantitation of sprouts per spheroid for 27 spheroids from 
3 independent experiments; Kruskal-Wallis statistical test *** = 
p<0.001, ns = not significant. Aortic rings from C57BL/6 mice were 
cultured in the presence of 20 µg/ml mIgG1 (CON), C2 or C4. [G] 
Representative images. Scale bars are equal to 200 µm. [H] 
Quantitation of tubes formed per ring, data from 30 rings, at least 6 
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mice were used for each condition; Kruskal-Wallis statistical test *** = 
p<0.001, ns = not significant. [I] Mmrn2 expression can be efficiently 
knocked down by siRNA duplexes in HUVEC, as determined by qPCR. 
Relative expression was determined by normalising expression to 
flotillin2. Kruskal-Wallis statistical test * = p<0.05. [J] Endothelial 
sprout outgrowth after 16 hours VEGF treatment of control or mmrn2 
targeted siRNA treated HUVEC spheroids. Quantitation of sprouts for 27 
spheroids (9 spheroids from 3 cords); Kruskal-Wallis statistical test 
p<0.001. [K] Representative images of sponge implants injected with 
bFGF and mIgG1 (CON) or C4 antibody. [L] Quantitation of cellular 
invasion into these sponge implants by threshold analysis of 
haematoxylin and eosin stained cellular material; Mann-Whitney 
statistical test p<0.01. [M] Quantitation of vessel density from K; 
Mann-Whitney statistical test p<0.001. 
 
Figure 7 - MMRN2-CLEC14A interaction blocking antibody inhibits 
tumour growth. [A] Mice injected with LLC were treated with 100 µg 
injections of mIgG1 (black line with dots; n=7) or C4 antibody (black 
line with squares; n=7); two-way ANOVA statistical analysis, ** = 
p<0.01, *** = p<0.001. [B] Representative images of LLC tumours. [C] 
Endpoint tumour weight for 7 mIgG1 treated mice (dots) and 7 C4 
antibody treated mice (squares); Mann-Whitney statistical test 
p<0.001. [D] Representative images of immunofluorescent staining of 
LLC tumour sections stained for murine CD31. Scale bars are equal to 
100 µm. Quantitation of vessel density [E] and percentage endothelial 
coverage [F] from mice treated with mIgG1 or C4 antibody; Mann-
Whitney statistical test p<0.001.  
 
Figure 8 - CLEC14A-MMRN2 binding is an important component of 
endothelial sprout formation and a regulator of tumour growth. ECM = 
extracellular matrix, PM = plasma membrane. 
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